Use of a T-cell based test for detection of TB infection among immunocompromised patients

¹ Emerging Bacterial Pathogens Unit, San Raffaele Scientific Institute, IRCCS, Milan, Italy; and Istituto Villa Marelli, Ospedale Niguarda Ca' Granda, Milan, Italy
² Istituto Villa Marelli, Ospedale Niguarda Ca' Granda, Milan, Italy
³ Emerging Bacterial Pathogens Unit, San Raffaele Scientific Institute, IRCCS, Milan, Italy
⁴ WHO Collaborating Centre for Tuberculosis and Lung Disease, S. Maugeri Foundation, IRCCS, Tradate, Italy
⁵ Ospedale Niguarda Ca' Granda, Milan, Italy

^* To whom correspondence should be addressed. E-mail: cirillo.daniela{at}hsr.it.

	Abstract

Overall, 44.2% of the contacts were positive by T-SPOT.TB, 17.4% by TST (concordance 67.8%, =0.34, p<0.0001). The apparent prevalence of infection fell from 25.9% to 14.5% with the TST with increasing immunosuppression, although this difference was not significant (p=0.12). In contrast, the apparent prevalence of infection with the T-SPOT.TB test was unaffected at 44.6% and 44.3% respectively. The T-SPOT.TB test had an overall indeterminate rate of 4.3% and this was also unaffected by the level of immunosuppression.

Our study suggests that T-SPOT.TB maintains sensitivity and performance in immunocompromised patients identifying a large number of truly-infected patients anergic to TST.

This article has been cited by other articles:

				U. Sester, H. Wilkens, K. van Bentum, M. Singh, G. W. Sybrecht, H-J. Schafers, and M. Sester Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs Eur. Respir. J., September 1, 2009; 34(3): 702 - 710. [Abstract] [Full Text] [PDF]

				P. Mangat, P. Taylor, and S. Abraham Comment on: Possible miliary tuberculosis during adalimumab therapy with negative {gamma}-IFN release assays Rheumatology, September 1, 2009; 48(9): 1177 - 1178. [Full Text] [PDF]

				L. Richeldi, M. Losi, R. D'Amico, M. Luppi, A. Ferrari, C. Mussini, M. Codeluppi, S. Cocchi, F. Prati, V. Paci, et al. Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients Chest, July 1, 2009; 136(1): 198 - 204. [Abstract] [Full Text] [PDF]

				P.-A. Triverio, P.-O. Bridevaux, P. Roux-Lombard, L. Niksic, T. Rochat, P.-Y. Martin, P. Saudan, and J.-P. Janssens Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1952 - 1956. [Abstract] [Full Text] [PDF]

				S. M. BEHAR, D. S. SHIN, A. MAIER, J. COBLYN, S. HELFGOTT, and M. E. WEINBLATT Use of the T-SPOT.TB Assay to Detect Latent Tuberculosis Infection Among Rheumatic Disease Patients on Immunosuppressive Therapy J Rheumatol, March 1, 2009; 36(3): 546 - 551. [Abstract] [Full Text] [PDF]

				C. B. E. Chee, S. H. Gan, K. W. KhinMar, T. M. Barkham, C. K. Koh, S. Liang, and Y. T. Wang Comparison of Sensitivities of Two Commercial Gamma Interferon Release Assays for Pulmonary Tuberculosis J. Clin. Microbiol., June 1, 2008; 46(6): 1935 - 1940. [Abstract] [Full Text] [PDF]

				A. Strassburg, C. Jafari, M. Ernst, W. Lotz, and C. Lange Rapid diagnosis of pulmonary TB by BAL enzyme-linked immunospot assay in an immunocompromised host Eur. Respir. J., May 1, 2008; 31(5): 1132 - 1135. [Abstract] [Full Text] [PDF]

				P. Beffa, A. Zellweger, J-P. Janssens, P. Wrighton-Smith, and J-P. Zellweger Indeterminate test results of T-SPOTTM.TB performed under routine field conditions Eur. Respir. J., April 1, 2008; 31(4): 842 - 846. [Abstract] [Full Text] [PDF]

				D. P.S. Dosanjh, T. S.C. Hinks, J. A. Innes, J. J. Deeks, G. Pasvol, S. Hackforth, H. Varia, K. A. Millington, R. Gunatheesan, V. Guyot-Revol, et al. Improved Diagnostic Evaluation of Suspected Tuberculosis Ann Intern Med, March 4, 2008; 148(5): 325 - 336. [Abstract] [Full Text] [PDF]

				W. P. J. Franken, B. F. P. J. Koster, A. W. J. Bossink, S. F. T. Thijsen, J. J. M. Bouwman, J. T. van Dissel, and S. M. Arend Follow-Up Study of Tuberculosis-Exposed Supermarket Customers with Negative Tuberculin Skin Test Results in Association with Positive Gamma Interferon Release Assay Results Clin. Vaccine Immunol., September 1, 2007; 14(9): 1239 - 1241. [Abstract] [Full Text] [PDF]

				R. Diel, P. Wrighton-Smith, and J-P. Zellweger Cost-effectiveness of interferon-{gamma} release assay testing for the treatment of latent tuberculosis Eur. Respir. J., August 1, 2007; 30(2): 321 - 332. [Abstract] [Full Text] [PDF]

				E. Porsa, L. Cheng, and E. A. Graviss Comparison of an ESAT-6/CFP-10 Peptide-Based Enzyme-Linked Immunospot Assay to a Tuberculin Skin Test for Screening of a Population at Moderate Risk of Contracting Tuberculosis Clin. Vaccine Immunol., June 1, 2007; 14(6): 714 - 719. [Abstract] [Full Text] [PDF]

				R. Diel, A. Nienhaus, and R. Loddenkemper Cost-effectiveness of Interferon-{gamma} Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany Chest, May 1, 2007; 131(5): 1424 - 1434. [Abstract] [Full Text] [PDF]

				D. Menzies, M. Pai, and G. Comstock Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research Ann Intern Med, March 6, 2007; 146(5): 340 - 354. [Abstract] [Full Text] [PDF]

				P. D. O. Davies and F. Drobniewski The use of interferon-{gamma}-based blood tests for the detection of latent tuberculosis infection. Eur. Respir. J., July 1, 2006; 28(1): 1 - 3. [Full Text] [PDF]